शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

BSEISHITA DRUGS & INDUSTRIES LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 3 Nov, 2026 · 17:20 IST

Standalone September 2026 quarter results approved; prior figures regrouped and upgrade advances

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction

Awaiting price reaction for this filing.

AI summary

Standalone results for the quarter ended 30 September 2026 were approved; no clear year-on-year revenue or profit comparison is available in the filing. Limited review raised no concerns. Prior-quarter figures were regrouped for comparability. Standalone half year ended 30 September 2026 operating cash flow was Rs 54.14 lakh. Schedule M upgrade is nearing completion; Rs 488 lakh was spent. HDFC drew Rs 51.90 lakh from a Rs 975 lakh term loan.

Likely market impact

Low debt and positive cash flow support resilience. The upgrade aids compliance, but regrouped prior figures and unclear earnings cloud the outlook.

By the numbersStandalone · Q2 FY27 vs Q2 FY26
Q2 FY27Q2 FY26Change
Revenue₹3.03 Cr₹3.07 Cr−1.1%
Operating profit₹0.06 Cr₹0.15 Cr−64.2%
Profit after tax₹0.16 Cr₹0.14 Cr+12.2%
EBITDA margin5.4%6.0%−0.7 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.